在埃塞俄比亚市场上销售的不同品牌的克拉里胺片的质量;对未来的影响
Workye Tsehayu Bayu1,2, Gebremariam Ketema1, Haile Kassahun1
1Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
JAC-antimicrobial resistance
|December 8, 2025
概括
质量控制测试证实,埃塞俄比亚所有经过测试的克拉里胺品牌都符合要求的标准. 这确保了有效的治疗,并支持了国家抗微生物耐药性制战略.
科学领域:
- 制药科学 制药科学
- 微生物学 微生物学
- 公共卫生 公共卫生
背景情况:
- 包括埃塞俄比亚在内的非洲的劣质抗生素有助于抗菌素耐药性 (AMR).
- 泛非注册和加强监测等举措旨在减少低标准抗生素的可用性.
- 评估抗生素质量对于有效制AMR至关重要.
研究的目的:
- 为了评估埃塞俄比亚可用的各种克拉里胺片品牌的质量.
- 确保国家医疗保健中使用的关键抗生素的药品质量.
主要方法:
- 在埃塞俄比亚药房购买了来自12个品牌的120个克拉里胺500毫克片.
- 质量控制测试包括视觉检查,重量变化,硬度,分解,溶解和测试.
- 测试遵循美国药典 (USP) 和世界卫生组织 (WHO) 的指南.
主要成果:
- 所有克拉里思罗米辛品牌都通过了活性药物成分的识别测试.
- 重量变化,硬度和分解时间符合USP规格.
- 药物含量在95.14%至100.44%之间,溶解测试在可接受的USP范围内.
结论:
- 在埃塞俄比亚市场上销售的所有评估的克拉里胺品牌都符合要求的质量标准.
- 这些经过质量保证的清红素产品可可靠地用于患者治疗.
- 确保抗生素质量对于埃塞俄比亚有效的抗菌素耐药性制战略至关重要.
相关概念视频
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
284
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
284
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
135
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
135
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
167
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
167
Clinically Relevant Drug Product Specifications: Methods of Establishment
186
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
186
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
157
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
157
Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141


